Multiple Sclerosis Journal · 2020 · 14 citations · 32 references
MedicineHematologyImmunologyAutoimmunityCell TherapyStem Cell TransplantationAutologous Stem Cell TransplantationConditioning RegimensHematopoietic Stem Cell TransplantationImmunosuppression ManagementMultiple SclerosisComparative Clinical TrialsConditioning Regimen OptimizationLong-term Efficacy AssessmentLong-term Efficacy EvaluationMultiple Sclerosis TherapySupportive ManagementTreatment Algorithm Development
The most effective treatment at halting inflammation in patients with highly active multiple sclerosis (MS) is immune ablation followed by autologous hematopoietic stem cell transplantation (AHSCT). Better patient selection and supportive management, as well as advances in conditioning regimens have resulted in improved safety with AHSCT. However, which comorbidities or prior therapies increase the risks associated with AHSCT still need to be determined. In addition, there is still debate as to which AHSCT conditioning regimen offers the best balance of long-term efficacy and safety. New studies comparing AHSCT with highly effective disease-modifying therapies will help to inform on the ideal placement of AHSCT in the treatment algorithm. Currently, many centers are experienced and use AHSCT to treat select patients with MS, contributing to ongoing registries and clinical trials which will help answer these questions.
32
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Life Sciences, Immunology, Neurology +17
The prevalence of MS in the United States
Mitchell T. Wallin, William J. Culpepper, Jonathan D. Campbell et al. · Neurology · 2019 · 1.1K citations · Full text